收费全文 | 1564998篇 |
免费 | 116106篇 |
国内免费 | 6459篇 |
耳鼻咽喉 | 18684篇 |
儿科学 | 50803篇 |
妇产科学 | 40465篇 |
基础医学 | 208565篇 |
口腔科学 | 38550篇 |
临床医学 | 137621篇 |
内科学 | 318474篇 |
皮肤病学 | 33207篇 |
神经病学 | 130915篇 |
特种医学 | 66369篇 |
外国民族医学 | 276篇 |
外科学 | 248898篇 |
综合类 | 34803篇 |
现状与发展 | 3篇 |
一般理论 | 443篇 |
预防医学 | 128126篇 |
眼科学 | 31781篇 |
药学 | 106810篇 |
6篇 | |
中国医学 | 2914篇 |
肿瘤学 | 89850篇 |
2018年 | 36738篇 |
2017年 | 29242篇 |
2016年 | 34427篇 |
2015年 | 16284篇 |
2014年 | 22223篇 |
2013年 | 32426篇 |
2012年 | 45899篇 |
2011年 | 63325篇 |
2010年 | 44920篇 |
2009年 | 37265篇 |
2008年 | 59686篇 |
2007年 | 65678篇 |
2006年 | 43096篇 |
2005年 | 43774篇 |
2004年 | 43250篇 |
2003年 | 43994篇 |
2002年 | 39582篇 |
2001年 | 66773篇 |
2000年 | 68837篇 |
1999年 | 57130篇 |
1998年 | 17385篇 |
1997年 | 15629篇 |
1996年 | 16422篇 |
1995年 | 16639篇 |
1994年 | 15480篇 |
1993年 | 14470篇 |
1992年 | 47355篇 |
1991年 | 46019篇 |
1990年 | 44261篇 |
1989年 | 42080篇 |
1988年 | 38977篇 |
1987年 | 38310篇 |
1986年 | 36043篇 |
1985年 | 34845篇 |
1984年 | 26552篇 |
1983年 | 22279篇 |
1982年 | 14090篇 |
1981年 | 12578篇 |
1980年 | 11959篇 |
1979年 | 23708篇 |
1978年 | 17209篇 |
1977年 | 14452篇 |
1976年 | 13294篇 |
1975年 | 13774篇 |
1974年 | 16168篇 |
1973年 | 15444篇 |
1972年 | 14200篇 |
1971年 | 13048篇 |
1970年 | 11929篇 |
1969年 | 11153篇 |
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Background
Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain.Methods
We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male).Results
Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians.Conclusions
Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation. 相似文献Background and aims
It is not known whether non alcoholic fatty liver disease (NAFLD) is a risk factor for diabetes in non obese, non centrally-obese subjects. Our aim was to investigate relationships between fatty liver, insulin resistance and a biomarker score for liver fibrosis with incident diabetes at follow up, in subjects who were neither obese nor centrally-obese.Methods and results
As many as 70,303 subjects with a body mass index (BMI) < 25 kg/m2 and without diabetes were followed up for a maximum of 7.9 years. At baseline, fatty liver was identified by liver ultrasound, insulin resistance (IR) by homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0, and central obesity by waist circumference (waist circumference ≥90 cm (men) and ≥85 cm (women). The Fibrosis-4 (FIB-4 score) was used to estimate extent of liver fibrosis. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (aHRs) for incident diabetes. As many as 852 incident cases of diabetes occurred during follow up (median [IQR] 3.71 [2.03] years). Mean ± SD BMI was 22.8 ± 1.8 and 21.7 ± 2.0 kg/m2 in subjects with and without diabetes at follow up. In subjects without central obesity and with fatty liver, aHRs (95% CI) for incident diabetes at follow up were 2.17 (1.56, 3.03) for men, and 2.86 (1.50,5.46) for women. Similar aHRs for incident diabetes occurred with fatty liver, IR and the highest quartile of FIB-4 combined, in men; and there was a non significant trend toward increased risk in women.Conclusions
In normal weight, non-centrally obese subjects NAFLD is an independent risk factor for incident diabetes. 相似文献Areas covered: Approximately 10–45% of patients undergoing head-and-neck cancers surgery develop SSIs. SSIs can lead to delayed wound healing, increased morbidity and mortality as well as costs. Consequently, SSIs need to be avoided where possible, as even the surgery itself impacts on patients’ subsequent activities and their quality of life, which is exacerbated by SSIs. Several risk factors for SSIs need to be considered to reduce future rates, and care is also needed in the selection and duration of antibiotic prophylaxis.
Expert commentary: Head and neck surgeons should give personalized care especially to patients at high risk of SSIs. Such patients include those who have had chemoradiotherapy and need reconstructive surgery, and patients from lower and middle-income countries and from poorer communities in high income countries, who often have high levels of co-morbidity because of resource constraints. 相似文献